文献速递头颈部肿瘤放疗

鼻咽癌调强放疗后医生与患者报告口干症的临床及剂量学预测因素

Clinical and dosimetric predictors of physician and patient reported xerostomia following intensity modulated radiotherapy for nasopharyngeal cancer - A prospective cohort analysis.
PubMed 文献 · Radiother Oncol · 2019-06-29

该前瞻性队列分析纳入172例局部晚期鼻咽癌患者,比较医生基于RTOG评分与患者基于EORTC QLQ-HN35报告的口干症,并分析其与剂量学及临床参数的关系。结果显示医生报告口干症水平持续低于患者报告,放疗后3个月口干症发生率分别为58%(E1)、70%(E2)和51%(E3),2年时分别为26%、36%和21%;腮腺平均Dmean为41.5 Gy,未发现剂量学参数与口干症显著相关。

要点

  • 医生报告的口干症水平持续低于患者自报口干。
  • 放疗后3个月口干症发生率高于2年时,1年与2年接近。
  • 腮腺平均Dmean为41.5 Gy,未发现剂量学参数与口干症显著相关。

核心结论

  • 调强放疗后仍有相当比例患者存在长期口干症。
  • 本研究未观察到口干症与腮腺剂量效应关系。

研究设计与样本

  • 前瞻性队列分析,纳入172例局部晚期鼻咽癌患者,均接受调强放疗和化疗。
  • 口干症评估采用医生RTOG评分(E1)、患者EORTC QLQ-HN35口干(E2)和唾液黏稠(E3)。
  • 主要终点为调强放疗完成后2年存在中重度口干症。

主要发现

  • 医生报告口干症(E1)水平随时间持续低于患者报告口干(E2)。
  • 放疗后3个月口干症发生率:E1为58%、E2为70%、E3为51%。
  • 放疗后2年口干症发生率:E1为26%、E2为36%、E3为21%。
  • 放疗后1年口干症发生率与2年接近(三个终点均如此)。
  • 腮腺平均Dmean为41.5 Gy(范围31.0–65.9 Gy,中位数40.7 Gy)。

关键数值与推荐

  • 医生报告口干症基于RTOG morbidity score(E1)。
  • 患者报告口干症基于EORTC QLQ-HN35问卷(E2口干、E3唾液黏稠)。

临床怎么用

  • 应重视患者自报口干症,医生报告可能低估症状负担。
  • 调强放疗后需长期随访口干症,尤其关注1–2年持续症状。
  • 即使腮腺平均剂量在41.5 Gy左右,仍需个体化评估口干风险。

局限性

  • 本研究未观察到剂量学参数与口干症的显著关联,可能受样本量或剂量范围限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: To compare physician and patient reported xerostomia and correlate xerostomia with dosimetric and clinical parameters for nasopharyngeal cancer (NPC) patients treated with intensity modulated radiotherapy (IMRT) and chemotherapy. PATIENTS AND METHODS: We analyzed the data of 172 patients with locally advanced NPC. Xerostomia was evaluated via physician-rated xerostomia based on RTOG morbidity score (E1), patient-rated dry mouth (E2) and patient-rated sticky saliva (E3) based on EORTC QLQ-HN35 questionnaire. Primary endpoint was the presence of moderate to severe xerostomia at 2-year after completion of IMRT. RESULTS: The levels of physician reported xerostomia (E1) were consistently lower than patient reported dry mouth (E2) over time. The incidence of patients with xerostomia at 3-month post RT was 58% based on E1, 70% based on E2, and 51% based on E3. The corresponding incidence rates at 2-year post RT was 26% (E1), 36% (E2) and 21% (E3). The incidence of patients with xerostomia at 1-year post RT was close to that at 2-year post RT for all the 3 endpoints. The average Dmean of parotid glands was 41.5 Gy (range: 31.0 Gy-65.9 Gy, median: 40.7 Gy). No dosimetric parameters were significantly associated with xerostomia. CONCLUSION: Significant proportion of patients still experienced long term xerostomia with IMRT. Dose-effect relationships between xerostomia and the parotid glands were not observed in this study.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Sommat K, Hussain A, Ong WS, et al. Clinical and dosimetric predictors of physician and patient reported xerostomia following intensity modulated radiotherapy for nasopharyngeal cancer - A prospective cohort analysis. Radiother Oncol. 2019. PMID: 31265972. doi:10.1016/j.radonc.2019.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。